US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with Mundipharma International Corporation Limited (MICL), Mundipharma Medical Company (MMCo), and Acrotech Biopharma Inc. (Acrotech) for the commercialization of Folotyn (pralatrexate) in China. The financial details of the agreement have not been disclosed.
Folotyn (Pralatrexate) for Peripheral T-cell Lymphoma (PTCL)
Pralatrexate, a dihydrofolate reductase inhibitor, is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The product has received approval from both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) for PTCL. Under the terms of the agreement, CASI will assume MICL’s rights and obligations related to the commercialization of the drug in China. The patent for pralatrexate is set to expire on May 31, 2025.
Market Competition for T-cell Lymphoma Treatments in China
Shenzhen Chipscreen Biosciences Co., Ltd’s (SHA: 688321) Epidaza (chidamide) and Kyowa Hakko Kirin Co., Ltd.’s Poteligeo (mogamulizumab) are both available on the market in China for the treatment of T-cell lymphoma. However, none of the three drugs, including Folotyn, have been included in the National Reimbursement Drug List (NRDL), which could impact their accessibility and affordability for patients.-Fineline Info & Tech
